Literature DB >> 16498648

Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation.

Hironori Haga1, Hiroto Egawa, Yasuhiro Fujimoto, Mikiko Ueda, Aya Miyagawa-Hayashino, Takaki Sakurai, Tomoko Okuno, Itsuko Koyanagi, Yasutsugu Takada, Toshiaki Manabe.   

Abstract

Complement C4d deposition in graft capillaries has been reported to be associated with antibody-mediated rejection in kidney and other solid organ transplantation. The correlation of C4d deposits and humoral rejection in liver transplants, however, is not well understood. We investigated the C4d immunostaining pattern in 34 patients whose liver biopsy was taken within the first 3 postoperative weeks for suspected acute rejection after ABO blood type-incompatible liver transplantation. The staining pattern was classified as positive (portal stromal staining), indeterminate (endothelial staining only), and negative (no staining). Positive C4d immunostaining was seen in 17 (50%) patients and was significantly associated with high (x64 or more) postoperative antidonor A/B antibody (immunoglobulin M (IgM)) titers (88 vs. 35%, P = 0.002) and poorer overall survival rate (41 vs. 88%, P = 0.007). Ten of 11 (91%) cases with histological acute humoral rejection (periportal edema and necrosis (PEN) or portal hemorrhagic edema) were positive for C4d, all of which showed high postoperative antibody titers. The other histologies associated with C4d positivity was purulent cholangitis (n = 4), coagulative hepatocyte necrosis (n = 1), acute cellular rejection (n = 1), and hepatocanalicular cholestasis (n = 1). Full clinical recovery was observed in only 6 of 17 (35%) C4d-positive patients, and tended to be associated with a lower rejection activity index (RAI). In conclusion, our study indicates that C4d deposits in the portal stroma can be a hallmark of acute humoral rejection in ABO-incompatible liver transplantation, and allograft damage can be reversible in a minority of cases. Copyright 2006 AASLD

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16498648     DOI: 10.1002/lt.20652

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  17 in total

Review 1.  [Current aspects of liver allograft pathology].

Authors:  U Drebber; M Torbenson; I Wedemeyer; H P Dienes
Journal:  Pathologe       Date:  2011-03       Impact factor: 1.011

2.  Positive C4d staining of the portal vein endothelium in the liver of patients with biliary atresia: a role of humoral immunity in ongoing liver fibrosis.

Authors:  Sorahiko Fujisawa; Toshihiro Muraji; Naoya Sakamoto; Naoki Hosaka; Satoshi Matsuda; Hajime Kawakami; Misako Hirai; Toshihiro Yanai
Journal:  Pediatr Surg Int       Date:  2014-07-27       Impact factor: 1.827

Review 3.  ABO-compatible liver allograft antibody-mediated rejection: an update.

Authors:  Anthony J Demetris; Adriana Zeevi; Jacqueline G O'Leary
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

Review 4.  [Histopathology in liver transplantation].

Authors:  U Drebber; H P Dienes
Journal:  Pathologe       Date:  2008-02       Impact factor: 1.011

5.  Impact of Antibodies That React With Liver Tissue and Donor-Specific Anti-HLA Antibodies in Pediatric Idiopathic Posttransplantation Hepatitis.

Authors:  Yoshihiro Hirata; Atsushi Yoshizawa; Hiroto Egawa; Daisuke Ueda; Shinya Okamoto; Hideaki Okajima; Kimiko Yurugi; Rie Hishida; Hideyo Hirai; Aya Miyagawa-Hayashino; Taira Maekawa; Hironori Haga; Sinji Uemoto
Journal:  Transplantation       Date:  2017-05       Impact factor: 4.939

6.  Long-term Outcomes of ABO-incompatible Pediatric Living Donor Liver Transplantation.

Authors:  Masaki Honda; Yasuhiko Sugawara; Masashi Kadohisa; Keita Shimata; Masataka Sakisaka; Daiki Yoshii; Keiichi Uto; Shintaro Hayashida; Yuki Ohya; Hidekazu Yamamoto; Hirotoshi Yamamoto; Yukihiro Inomata; Taizo Hibi
Journal:  Transplantation       Date:  2018-10       Impact factor: 4.939

7.  ABO incompatible liver transplantation as a bridge to treat HELLP syndrome.

Authors:  Kathleen Connor; Raymond A Rubin; Roshan Shrestha; Mark Johnson; Marty Sellers; Brad Butler
Journal:  Gastroenterol Res Pract       Date:  2009-09-28       Impact factor: 2.260

8.  Significance of semiquantitative assessment of preformed donor-specific antibody using luminex single bead assay in living related liver transplantation.

Authors:  Atsushi Yoshizawa; Hiroto Egawa; Kimiko Yurugi; Rie Hishida; Hiroaki Tsuji; Eiji Ashihara; Aya Miyagawa-Hayashino; Satoshi Teramukai; Taira Maekawa; Hironori Haga; Sinji Uemoto
Journal:  Clin Dev Immunol       Date:  2013-05-29

Review 9.  Current techniques for AB0-incompatible living donor liver transplantation.

Authors:  Silke Rummler; Astrid Bauschke; Erik Bärthel; Heike Jütte; Katrin Maier; Patrice Ziehm; Christina Malessa; Utz Settmacher
Journal:  World J Transplant       Date:  2016-09-24

10.  Adult Living Donor Liver Transplantation Across ABO-Incompatibility.

Authors:  Chen-Fang Lee; Chih-Hsien Cheng; Yu-Chao Wang; Ruey-Shyang Soong; Tsung-Han Wu; Hong-Shiue Chou; Ting-Jung Wu; Kun-Ming Chan; Ching-Song Lee; Wei-Chen Lee
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.